Detalles de la búsqueda
1.
Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
Eur J Haematol
; 110(3): 262-270, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36398467
2.
Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.
Clin Exp Immunol
; 207(2): 218-226, 2022 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35020840
3.
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
Ann Hematol
; 101(9): 1905-1914, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869984
4.
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
Haemophilia
; 28(1): 18-26, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761474
5.
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.
Eur J Haematol
; 109(4): 351-363, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35746830
6.
Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: A retrospective primary care database study.
Neurourol Urodyn
; 38(5): 1278-1289, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30924184
7.
Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE.
Int J Urol
; 26(9): 890-896, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31302930
8.
A critical appraisal of the principal guidelines for neurogenic lower urinary tract dysfunction using the AGREE II instrument.
Neurourol Urodyn
; 37(8): 2945-2950, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30058737
9.
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Neurourol Urodyn
; 37(3): 986-996, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29140559
10.
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
BMC Urol
; 18(1): 76, 2018 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30180826
11.
Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Qual Life Res
; 26(5): 1187-1195, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27896711
12.
A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
BMC Urol
; 17(1): 36, 2017 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28532455
13.
Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Int J Clin Pract
; 71(10)2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28906080
14.
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
J Urol
; 196(3): 809-18, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27063854
15.
Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
BJU Int
; 117(1): 165-72, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25907003
16.
A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Infection
; 44(5): 599-606, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27062378
17.
Patient-reported outcomes with the ß3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder.
Neurourol Urodyn
; 35(8): 987-994, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26288118
18.
Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Value Health
; 18(6): 783-90, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26409605
19.
Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
BMC Urol
; 15: 41, 2015 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25956727
20.
Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Value Health
; 17(8): 823-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25498777